Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC).

AIMS Reducing maternal mortality is a World Health Organization (WHO) global health goal. Although maternal deaths due to haemorrhage and infection are declining, those related to heart disease are increasing and are now the most important cause in western countries. The aim is to define contemporary diagnosis-specific outcomes in pregnant women with heart disease. METHODS AND RESULTS From 2007 to 2018, pregnant women with heart disease were prospectively enrolled in the Registry Of Pregnancy And Cardiac disease (ROPAC). Primary outcome was maternal mortality or heart failure, secondary outcomes were other cardiac, obstetric, and foetal complications. We enrolled 5739 pregnancies; the mean age was 29.5. Prevalent diagnoses were congenital (57%) and valvular heart disease (29%). Mortality (overall 0.6%) was highest in the pulmonary arterial hypertension (PAH) group (9%). Heart failure occurred in 11%, arrhythmias in 2%. Delivery was by Caesarean section in 44%. Obstetric and foetal complications occurred in 17% and 21%, respectively. The number of high-risk pregnancies (mWHO Class IV) increased from 0.7% in 2007-2010 to 10.9% in 2015-2018. Determinants for maternal complications were pre-pregnancy heart failure or New York Heart Association >II, systemic ejection fraction <40%, mWHO Class 4, and anticoagulants use. After an increase from 2007 to 2009, complication rates fell from 13.2% in 2010 to 9.3% in 2017. CONCLUSION Rates of maternal mortality or heart failure were high in women with heart disease. However, from 2010, these rates declined despite the inclusion of more high-risk pregnancies. Highest complication rates occurred in women with PAH.

[1]  R. Baggott.  DISEASE , 1947, Social Policy & Administration.

[2]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[3]  S. Siu,et al.  Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study. , 2018, Journal of the American College of Cardiology.

[4]  R. Hall,et al.  Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease , 2018, Circulation.

[5]  R. Hall,et al.  Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC) , 2017, European heart journal.

[6]  S. Vause,et al.  Pregnancy outcomes in women with mechanical prosthetic heart valves: a prospective descriptive population based study using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system , 2017, BJOG : an international journal of obstetrics and gynaecology.

[7]  Jun Ma,et al.  Anticoagulation regimens during pregnancy in patients with mechanical heart valves : a systematic review and meta – analysis , 2015 .

[8]  K. Sliwa,et al.  Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology , 2016, European journal of heart failure.

[9]  Christine H Morton,et al.  Recent Increases in the U.S. Maternal Mortality Rate: Disentangling Trends From Measurement Issues , 2016, Obstetrics and gynecology.

[10]  L. Iserin,et al.  Pregnancy outcomes in patients with pulmonary arterial hypertension associated with congenital heart disease , 2016, Heart.

[11]  N. Kouchoukos,et al.  Pregnancy after aortic root replacement in Loeys–Dietz syndrome: High risk of aortic dissection , 2016, American journal of medical genetics. Part A.

[12]  Patrick Gerland,et al.  National, regional, and global levels and trends in maternal mortality between 1990 and 2015 with scenario-based projections to 2030: a systematic analysis by the United Nations Maternal Mortality Estimation Inter-Agency Group , 2015, The Lancet.

[13]  T. Lahm,et al.  Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute , 2015, Pulmonary circulation.

[14]  R. Hall,et al.  Pregnancy in Women With a Mechanical Heart Valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). , 2015, Circulation.

[15]  A. Shroff,et al.  Aortic dissection and mortality associated with pregnancy in the United States. , 2015, Journal of the American College of Cardiology.

[16]  R. Hall,et al.  Is a planned caesarean section in women with cardiac disease beneficial? , 2014, Heart.

[17]  S. Kenyon,et al.  Saving Lives, Improving Mothers' Care: Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-2012 , 2014 .

[18]  P. Pieper,et al.  Pregnancy and pulmonary hypertension. , 2014, Best practice & research. Clinical obstetrics & gynaecology.

[19]  R. Hall,et al.  Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. , 2013, European heart journal.

[20]  S. Curtis,et al.  Low‐molecular‐weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study , 2012, BJOG : an international journal of obstetrics and gynaecology.

[21]  Mike Kirby,et al.  ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy , 2012 .

[22]  M. Humbert,et al.  Pregnancy outcomes in pulmonary arterial hypertension in the modern management era , 2012, European Respiratory Journal.

[23]  Mike Kirby,et al.  Guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology ( ESC ) , 2011 .

[24]  S. Siu,et al.  Cardiac outcomes after pregnancy in women with congenital heart disease , 2010, Heart.

[25]  B. Mulder,et al.  Predictors of pregnancy complications in women with congenital heart disease. , 2010, European heart journal.

[26]  J. Deanfield,et al.  The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric Cardiology (AEPC) , 2010 .

[27]  S. Siu,et al.  Pregnancy outcomes in women with dilated cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[28]  K. Dimopoulos,et al.  Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? , 2008, European heart journal.

[29]  A Metin Gülmezoglu,et al.  WHO analysis of causes of maternal death: a systematic review , 2006, The Lancet.

[30]  P. Khairy,et al.  Pregnancy Outcomes in Women With Congenital Heart Disease , 2006, Circulation.

[31]  M. Kramer,et al.  Pregnancy Outcome in Patients With Pulmonary Arterial Hypertension Receiving Prostacyclin Therapy , 2005, Obstetrics and gynecology.

[32]  A. Zwinderman,et al.  Pregnancy and aortic root growth in the Marfan syndrome: a prospective study , 2005 .

[33]  C. Autore,et al.  Risk associated with pregnancy in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[34]  S. Siu,et al.  Prospective Multicenter Study of Pregnancy Outcomes in Women With Heart Disease , 2001, Circulation.